Competitive landscape — RNAi & oligonucleotide therapeutics for obesity¶
Ogur Explore · mapped and synthesized from a single research thesis. Leads are flagged for primary-source verification, never asserted as confirmed.
Archived draft — sourcing is source-NAME level, not link level. This 2026-07-09 sample names the source that surfaced each row (
gpatents,sec,openalex) but does not carry the resolvable identifiers — NCT ids, patent publication numbers, OpenAlex ids — that make a claim one click from its record. It therefore does not meet the project's provenance contract and must not be sent to a customer as-is. The shipped, link-grounded version of this landscape isarchived_data/obesity_rnai_explore/competitive_briefing_obesity_rnai_v1_full.md(in the repository), where every table row resolves to a public record; this file is kept as the run's historical artifact.
Research thesis: "siRNA, RNAi and antimiR oligonucleotide therapeutics for obesity and metabolic disease, including INHBE/activin-E and ALK7 (ACVR1C) programs, adipocyte, appetite and hepatic metabolic targets, and preclinical China- and Korea-based candidates." Scope: siRNA / RNAi / antimiR × { INHBE (anchor), ACVR1C/ALK7, GRB14, ANGPTL¾/8, APOC3, AGT, FAM13A, GDF15, PNPLA3, HSD17B13, … } × obesity, type-2 diabetes, MASH/NASH, dyslipidemia.
1. The landscape at a glance¶
16 named obesity-RNAi assets and 11 active companies recovered on-thesis, plus 49 additional core players surfaced as leads. The field is early — most assets are Phase 1 or preclinical — with a tight target consensus (INHBE / activin-E) and a heavy China footprint alongside the US RNAi majors.
Named assets (recovered from the deck)¶
| asset | company | target | source |
|---|---|---|---|
| ARO-INHBE | Arrowhead Pharmaceuticals | INHBE | gpatents · sec |
| ARO-ALK7 | Arrowhead Pharmaceuticals | ACVR1C (ALK7) | gpatents |
| WVE-007 | Wave Life Sciences | INHBE | openalex |
| ALN-4324 | Alnylam | GRB14 | gpatents |
| ALN-2232 | Alnylam | ACVR1C | gpatents |
| (INHBE) | Alnylam | INHBE | gpatents |
| (ANGPTL4) | Alnylam | ANGPTL4 | gpatents |
| BC-006 | BaseCure Therapeutics | INHBE | gpatents · openalex |
| Cotsiranib | Sirnaomics | TGF-β1 + COX-2 | gpatents |
| (INHBE) | Suzhou Siran Biotechnology (SiranBio) | INHBE | gpatents |
| (ACVR1C) | Suzhou Siran Biotechnology (SiranBio) | ACVR1C | gpatents |
| (ANGPTL3) | Shenzhen Salubris | ANGPTL3 | gpatents |
| (INHBE) | Shanghai Argo Biopharma | INHBE | gpatents |
| OLX702C | OliX Pharmaceuticals | APOC3 | gpatents |
| (FAM13A) | Amgen | FAM13A | gpatents |
| (AGT) | Sirius Therapeutics | AGT | gpatents |
Additional players surfaced (top core leads — each needs primary-source verification)¶
The strategically notable finding: the GLP-1 incumbents and the RNAi platforms are both moving into obesity RNAi.
| company | modality | latest activity |
|---|---|---|
| Novo Nordisk | siRNA | 2026-02 |
| Eli Lilly | siRNA | 2026-05 |
| Novartis | RNAi | 2026-05 |
| Regeneron | siRNA | 2026-04 |
| Silence Therapeutics | siRNA | 2026-06 |
| Ionis | siRNA | 2026-03 |
| Boehringer Ingelheim | RNAi | 2025-07 |
| Suzhou Ribo Life Science | siRNA | 2026-04 |
| Insitro | RNAi (GCK) | 2026-02 |
| Empirico | siRNA (ANGPTL) | 2026-04 |
| Eddingpharm | siRNA (EDP167, ANGPTL) | 2026-03 |
| Shanghai Rona Therapeutics | siRNA | 2026-02 |
| Frontier Biotechnologies | siRNA | 2026-02 |
| Qilu Pharmaceutical | RNAi | 2026-03 |
| BeBetter Med | siRNA | 2026-02 |
Data note. Target focus is the target set disclosed in each company's patents/trials (company-level — a broad platform claim, not always the precise per-asset pair). Clinical stage (phase) is not shown: the public records surfaced for these mostly-preclinical, China-domestic assets do not carry a structured trial phase. Both are disclosure limits of the public record, not gaps in the search.
Deals & partnerships¶
No deal axis in this landscape — the obesity-RNAi benchmark tracks assets and companies only, so this pass scored no deals (unlike the cardiometabolic siRNA landscape, which carried 12). Corporate- development activity here is visible only indirectly, via the incumbents' own filings (Novo Nordisk, Eli Lilly, Boehringer entering the modality) — a signal that in-house build, not licensing, is the current mode.
2. Competitive positioning (INHBE-anchor obesity-RNAi set)¶
Where the recovered obesity-RNAi assets sit, against the GLP-1 standard of care that defines the market:
| lane | asset | company | target / mechanism | stage (public) |
|---|---|---|---|---|
| RNAi — front-runner | ARO-INHBE | Arrowhead | INHBE siRNA (GalNAc) | Phase ½ |
| RNAi — front-runner | WVE-007 | Wave Life Sciences | INHBE siRNA | Phase 1 |
| RNAi — receptor axis | ARO-ALK7 | Arrowhead | ACVR1C/ALK7 siRNA | preclinical |
| RNAi — diversifier | ALN-4324 | Alnylam | GRB14 siRNA | preclinical |
| RNAi — China | BC-006 | BaseCure | INHBE siRNA | Phase 1 |
| Incumbent SoC | semaglutide / tirzepatide | Novo Nordisk / Eli Lilly | GLP-1(/GIP) agonist | Approved |
Mechanism lanes observed: INHBE / activin-E silencing (siRNA) — the consensus anchor; ACVR1C/ALK7 receptor silencing (siRNA); adipose/GWAS diversifiers (GRB14, FAM13A, ANGPTL4); hepatic-metabolic (APOC3, ANGPTL3, PNPLA3); microRNA modulation (miR-22, antimiR — thinly represented). The whole field positions against injectable GLP-1 incumbency on durability (quarterly/biannual dosing) and mechanism (fat-specific, muscle-sparing).
3. Strategic briefing¶
Synthesized from the discovered landscape (the cited assets, companies and filings above). This pass was discovery + recall-focused; the analysis below is grounded in those findings — the automated multi-KIQ synthesizer briefing (as run for the siRNA landscape) is the natural follow-up.
Executive summary¶
The obesity-RNAi landscape has converged on a single anchor target — INHBE (inhibin βE / activin-E) — with the clearest cluster of any obesity mechanism outside the GLP-1 axis: Arrowhead (ARO-INHBE, Phase ½), Wave (WVE-007), Alnylam, BaseCure (BC-006), and the China cluster (SiranBio, Shanghai Argo) all file on INHBE, and Arrowhead + Alnylam + SiranBio extend to its receptor ALK7 (ACVR1C). The thesis is a durability and mechanism play against GLP-1 incumbency: where semaglutide/tirzepatide require weekly injection and carry tolerability and lean-mass-loss concerns, a GalNAc-siRNA silencing a liver-secreted obesity hormone offers quarterly-to-biannual dosing and a fat-specific, genetically- validated mechanism. The single most strategically important discovery this run is that the GLP-1 incumbents themselves — Novo Nordisk and Eli Lilly — are now filing double-stranded-oligonucleotide IP, alongside Novartis, Regeneron and Boehringer Ingelheim: the market leaders are hedging into the modality that could unseat their own franchises. The field is early (Phase 1 / preclinical) and heavily China-weighted (Salubris, Argo, SiranBio, Sirnaomics, BeBetter, Suzhou Ribo, Qilu), which means the in-license window for differentiated, non-INHBE targets is open now and narrowing.
Strategic implications¶
1. INHBE is crowded; the edge is the second target. With six+ recovered players on INHBE, the anchor is no longer differentiating — it is table stakes. The white space is the diversifier axis the discovery surfaced thinly: GRB14 (Alnylam ALN-4324), FAM13A (Amgen), ANGPTL4 (Alnylam), and the adipose/appetite GWAS genes. A program pairing INHBE silencing with a differentiated second mechanism — or leading with a validated non-INHBE target — is where a follower avoids a six-way race.
2. The incumbents' RNAi filings are the signal to watch. Novo Nordisk and Eli Lilly filing siRNA IP in obesity is not incremental — it is the market defining its own next wave. Their internal build (vs visible licensing) suggests the near-term BD action is acquiring the platform/target, not the asset: the Chinese INHBE innovators (SiranBio, Argo, Salubris) and the receptor-axis players are the most likely targets before incumbent programs mature and foreclose the space.
3. China owns the early-innovation density. A majority of the recovered non-US assets originate from Chinese biotechs, several patent-stage only (Salubris ANGPTL3, Argo/SiranBio INHBE, Sirius AGT). Western pharma that delays APAC engagement risks paying post-disclosure premiums; the patent-only visibility of these programs means they are reachable now, before a trial registration raises their profile.
What to watch (forward calls)¶
- Arrowhead's ARO-INHBE (Phase ½) is the field's clinical bar — its first weight-loss + body- composition readout will set the durability/efficacy benchmark every INHBE follower is measured against.
- A GLP-1 incumbent (Novo or Lilly) discloses or in-licenses an obesity-RNAi program within 12–18 months — the internal IP filings surfaced here are the leading indicator; the durability thesis is too strategically central for them to sit out.
- The receptor axis (ALK7/ACVR1C) is the next consensus target after INHBE — Arrowhead, Alnylam and SiranBio all filing there suggests it is where the second wave concentrates.
Key intelligence questions¶
Is there a consensus anchor target? — confidence: high. Yes: INHBE/activin-E is the anchor of the obesity-RNAi landscape, with Arrowhead (ARO-INHBE), Wave (WVE-007), Alnylam, BaseCure (BC-006), SiranBio and Shanghai Argo all filing on it, and the receptor ALK7 (ACVR1C) as the paired mechanism (Arrowhead ARO-ALK7, Alnylam ALN-2232, SiranBio). It is the durability/mechanism alternative to GLP-1.
Are the GLP-1 incumbents entering the modality? — confidence: high (leads flagged). Both Novo Nordisk and Eli Lilly surfaced as core net-new leads on double-stranded-oligonucleotide IP, alongside Novartis, Regeneron and Boehringer Ingelheim — the market leaders are building RNAi optionality. (Company- level patent evidence; specific obesity assets need primary-source verification.)
Does China dominate early innovation? — confidence: high. A majority of recovered non-US assets are Chinese (Shenzhen Salubris, Shanghai Argo, SiranBio, Sirnaomics, BeBetter Med, Suzhou Ribo, Qilu), most patent-stage — a disproportionate share of the early-innovation density, mirroring the cardiometabolic siRNA pattern.
How clinically mature is the field? — confidence: medium. Overwhelmingly early: the front-runners (ARO-INHBE Phase ½, WVE-007 Phase 1, BC-006 Phase 1) are the exceptions; most recovered assets are preclinical / patent-stage with no structured phase in the public record — high aggregate attrition risk.
Where is the BD white space? — confidence: medium. Off the crowded INHBE anchor: the differentiated diversifier targets the discovery surfaced thinly — GRB14 (Alnylam), FAM13A (Amgen), ANGPTL4 (Alnylam) — and the appetite/adipose GWAS axis. Leading with a validated non-INHBE target avoids the six-way anchor race.
Every asset and company above names the source that surfaced it, but this draft does not carry the resolvable identifiers that make a claim one click from its record — see the note at the top, and use the link-grounded brief for anything customer-facing. Discovered live from public sources against the research thesis; leads require analyst verification before being treated as confirmed competitors.